Study of Avastin (Bevacizumab) to Reverse Acquired Estrogen Independence in Previously Hormone Responsive Metastatic Breast Ca.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00240071|
Recruitment Status : Completed
First Posted : October 17, 2005
Results First Posted : September 27, 2011
Last Update Posted : March 19, 2018
University of Alabama at Birmingham
Information provided by (Responsible Party):
Carla Falkson, MD, University of Alabama at Birmingham
|Study Design||Intervention Model: Single Group Assignment; Masking: None (Open Label); Primary Purpose: Treatment|
Metastatic Breast Cancer
Drug: Hormonal therapy
|Recruitment Details||Recruitment started October 2005 - until March 2009. Kirklin Clinic at UAB, Birmingham AL and Georgia Cancer Center, Atlanta GA|
|Pre-assignment Details||The purpose of this study is to determine if acquired hormone therapy resistance can be reversed by Avastin (Bevacizumab), as measured by time to disease progression and evaluate toxicity of the combination of hormone treatment plus Avastin.|
A Phase II trial.